Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 31 Executives Received Annual Compensations for FY2013 of Over 100 Million Yen: Jiho Survey
July 9, 2014
- MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
- Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
- Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
July 7, 2014
- MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
July 7, 2014
- European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
July 7, 2014
- Nippon Kayaku Obtains Approval for Remicade Biosimilar
July 7, 2014
- Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
- Santen to Complete Acquisition of Ophthalmology Assets from Merck
July 4, 2014
- Taiho Submits Application for Additional Indication of Febrile Neutropenia for Zosyn
July 4, 2014
- BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
July 4, 2014
- Kyowa Kirin to Resume Development of Bardoxolone Methyl for CKD Patients with Type 2 Diabetes
July 4, 2014
- Poteligeo Re-Filed for Approval of Additional Indication of Untreated CCR4-Positive ATL
July 3, 2014
- Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
- Genzyme Japan Submits NDA for Oral Gaucher’s Disease Drug
July 3, 2014
- CMIC, JSR Set Up Joint Venture for Next-Generation Antibodies
July 3, 2014
- MTPC Plans Entry into Global Vaccine Business Starting with a Seasonal Influenza Vaccine
July 3, 2014
- Hospira Japan Appoints Former Mundipharma President Toyohara as Its New President
July 3, 2014
- Sawai, MTPC Agree on Transfer of Kashima Plant to Sawai
July 3, 2014
- Takeda Sets Up Japan Vaccine Unit Led by Ex-Sanofi R&D Head
July 2, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…